In millions, except per share items | Dec-31-22 | Dec-31-21 |
| 8-K | 10-K |
Revenues | 145.9 | 2.8 |
Revenue growth | 5204.6% | |
Cost of goods sold | 86.6 | 1.2 |
Gross profit | 59.3 | 1.5 |
Gross margin | 40.6% | 54.6% |
Selling, general and administrative [+] | 69.5 | 2.8 |
Sales and marketing | 12.6 | |
General and administrative | 56.9 | |
Research and development | 50.1 | |
Other operating expenses | 20.6 | -2.8 |
EBITDA [+] | -73.1 | |
EBITDA growth | -4964.2% | |
EBITDA margin | -50.1% | 54.6% |
Depreciation and amortization | 7.7 | |
EBIT [+] | -80.8 | 1.5 |
EBIT growth | -5479.4% | |
EBIT margin | -55.4% | 54.6% |
Non-recurring items [+] | -17.8 | 2.8 |
Asset impairment | 2.8 | |
Other income (expense), net [+] | -14.8 | -2.1 |
Gain (loss) on investments | | 0.0 |
Gain (loss) on foreign currency transactions | 0.3 | |
Change in fair value of warrants | | -1.9 |
Pre-tax income | -77.9 | -3.3 |
Income taxes | 0.4 | 0.0 |
Tax rate | | 0.0% |
Net income | -78.3 | -3.3 |
Net margin | -53.7% | -121.4% |
|
Basic EPS | | ($0.10) |
Diluted EPS | | ($0.10) |
|
Shares outstanding (basic) | | 32.8 |
Shares outstanding (diluted) | | 32.8 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |